
- Gemina raises $2.2m via a non-brokered private placement
- Placement is oversubscribed
VANCOUVER, BC, October 25, 2021 – Syniad Innovations Inc (“Syniad”) is pleased to announce that Gemina Laboratories Ltd. (“Gemina”) has successfully closed a non-brokered private placement. The placement, which was oversubscribed, raised gross proceeds of $2.2m at a price per share of $0.55 per Unit. Each Unit consists of one common share (a “Common Share”) of Gemina and one-half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Common Share at an exercise price of $0.80 per Common Share for a period of 24 months from the date of issuance, subject to acceleration if the trading price of the Common Shares equals or exceeds $2.00 for a period of 10 consecutive days.
Syniad co-founded Gemina in 2020, to create a world-leading biosensing company. Gemina’s objective is to deliver diagnostic testing at the point of need. Its technology platform has the potential to address a wide range of pathogens, for instance, the rapid testing of COVID-19, Influenza and a variety of other viruses and conditions.
Commenting on today’s announcement, John Davies, Syniad’s CEO, said, “Today’s financing is another great step forward for Gemina as it advances its first product – a rapid diagnostic test – based on its proprietary biosensing platform.”
Latest Posts

Patronus Technologies (Canada) Ltd Forms Strategic Alliance with QinetiQ UK Limited To Collaborate On Advanced Armour Development
Read More
Syniad Innovations’ 3R Circuits Achieves Major Milestone with Groundbreaking Nickel Laterite Processing Patent Application
Read More
Syniad Fuels Self-Driving Lab Ambition with AI Platform Investment to Revolutionize Drug Discovery
Read More